Aralez Pharmaceuticals Trading DAC has finalized the purchase of the rights to Toprol-XL in the U.S. and Authorized Generic from AstraZeneca. Read More »

Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »

ACADIA Pharmaceuticals' Phase II SERENE trial involving pimavanserin has begun. Read More »

The Female Health Co.'s transformational merger with Aspen Park Pharmaceuticals has been finalized with both sides agreeing to modified terms. Read More »

A licensing agreement with Norgine B.V. will give Valeant Pharmaceuticals the rights to the development and commercialization of NER1006 Powder for Oral Solution in the United States and Canada. Read More »

Valeant Pharmaceuticals and Progenics Pharmaceuticals have commercially released RELISTOR Tablets in the United States and it is now available for prescription. Read More »

ACADIA Pharmaceuticals has started its Phase II clinical trial of pimavanserin called SERENE to assess the medication’s ability to treat patients who have Alzheimer’s disease and are experiencing agitation. Read More »

Vertex Pharmaceuticals has released an update on the development of its upcoming Phase 3 program involving its investigational compound VX-661. Read More »

The Food and Drug Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of RESTASIS, both of which are free of preservatives. Read More »

The National Association of Chain Drug Stores is enlisting the help of pharmacy professionals to aid in reaching their goals by calling on them to vote on every level of the government. Read More »

Astellas USA Foundation has announced that it has appointed Moyra Knight its new president, replacing Jeffrey Winton in the position. Read More »

Acella Pharmaceuticals was recently approved to begin the development of a generic form of a sugar-free Bromfed DM cough syrup. Read More »

Tyr Pharma's Resolaris has been granted Fast Track designation by the Food and Drug Administration. Read More »

Braeburn Pharmaceuticals and Camurus have extended their partnership and license agreement to include buprenorphine combination products. Read More »

Cidara Therapeutics' data from its CD101 preclinical and clinical trials was presented at the 2016 American College of Clinical Pharmacy annual meeting and at the IDWeek 2016 meeting last month. Read More »

Eiger BioPharmaceuticals' hepatitis delta campaign has been launched across the country. Read More »

Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »

Sunovion Pharmaceuticals' acquisition of Cynapsus Therapeutics has been finalized through Sunovion's subsidiary Sunovion CNS Development Canada. Read More »

Newron Pharmaceuticals, in association with its partners Zambon and US WorldMeds, has resubmitted the U.S. New Drug Application in September seeking a complete Class 2 response by the U.S. Food and Drug Administration for Xadago, also known by its generic name, safinamide. Read More »

Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »